Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 06/02/2022

2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting External Link from June 3-7, 2022. The following tables include the oral and poster sessions containing DCTD staff speakers and co-authors.

Oral Sessions

Title Link
ASCO Town Hall: The Future of the Conduct of Clinical Trials After COVID-19; CTEP Perspective

Speaker: Margaret Mooney, MD, MS
Education Session External Link
June 4, 4:00 pm EDT
COVID-19 and Cancer: Advantages and Disadvantages of Immunotherapy: Immune checkpoint inhibitors and COVID-19: What are the risks of immune-related adverse events in patients with COVID-19?

Speaker: Elad Sharon, MD, MPH
Education Session External Link
June 6, 12:30 pm EDT

Poster Sessions

CSClinical Science Symposium; eePublication; OAOral Abstract Session; PPoster Presentation; PDPoster Discussion Session

Title Link
Abstract #
Racial/ethnic disparities in locoregional recurrence in hormone-receptor positive node-negative breast cancer patients enrolled in the TAILORx trial PD515 External Link
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma P2035 External Link
The interim result of a phase I/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma P2068 External Link
Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada OA2508 External Link
Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D P2616 External Link
Immune checkpoint inhibitor-induced diabetes mellitus across NCI trials P2668 External Link
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J) PD3009 External Link
Phase II study of vismodegib in patients with SMO or PTCH1 mutated: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T PD3010 External Link
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors
Presenter: Sarah Shin, MD
P3026 External Link
Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results P3035 External Link
Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446) P6089 External Link
Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population P6542 External Link
Representatives of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP) P6543 External Link
Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512) OA9502 External Link
Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers OA9507 External Link
Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C) PD10009 External Link
Biomarkers Beyond Histology in Contemporary Sarcoma Clinical Trials CS11509 External Link
A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma P11528 External Link
Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors

Presenter: Geraldine O’Sullivan Coyne, MD, PhD
P11545 External Link
Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial

Presenter: Hari Sankaran, PhD
eE17617 External Link
Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399 eE20606 External Link
Results of the DIAL study (NCI 10089), a randomized phase 2 trial of Varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL) PLBA7564 External Link
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with Copanlisib in patients with metastatic triple-negative breast cancer (TNBC) PTPS1128 External Link
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma PTPS3174 External Link
A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC) PTPS4604 External Link

Staff Kiosk Schedule — Booth #4043

Date Time Presenter
June 4 11:00 AM - 1:00 PM Lori Henderson, PhD
Cancer Therapy Evaluation Program
June 5 9:00 AM - 11:00 AM Sharad Verma, PhD
Developmental Therapeutics Program
1:00 PM - 3:00 PM Marc S. Ernstoff, MD
Developmental Therapeutics Program
3:00 PM - 5:00 PM Sundar Venkatachalam, PhD
Developmental Therapeutics Program
June 6 9:00 AM - 11:00 AM Sharad Verma, PhD
Developmental Therapeutics Program
11:00 AM - 1:00 PM Sundar Venkatachalam, PhD
Developmental Therapeutics Program